

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

Status: Recruiting

Eligibility Criteria

This study is NOT accepting healthy volunteers

Conditions & Interventions

Conditions:

Glioblastoma

Keywords:

Clinics and Surgery Center (CSC)

More Information

Description: To assess whether there is superiority of overall survival (OS) when enzastaurin rather than placebo is added to the regimen of temozolomide with radiation therapy followed by temozolomide for the treatment of patients with newly diagnosed glioblastoma in DGM1 biomarker-positive patients, regardless of MGMT methylation status.

Contact(s): Elizabeth Neil - neile@umn.edu

Principal Investigator: Elizabeth Neil

Phase: Phase III

IRB Number: STUDY00011956

System ID: NCT03776071

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.